

## PRESS RELEASE

Zug, April 9<sup>th</sup>, 2015

### **Rontis enters into exclusive distribution agreement with Nipro for Rontis interventional devices**

Rontis Corporation S.A. announces that its Swiss subsidiary Rontis AG (Zug, Switzerland) has signed an agreement with Nipro Medical Corporation (Miami, USA), the U.S. subsidiary of Nipro Corporation, for the **exclusive distribution of the Rontis IVC/IVR medical devices portfolio within the Asia Pacific & Oceania regions.**

During Q3 2013, **Rontis and Nipro** reached an agreement for the exclusive distribution and promotion by Nipro of Rontis coronary & peripheral products in **Latin America**. Over the last year, the two sides have held discussions at the highest level for the expansion of their cooperation in additional territories. Through the above-mentioned agreement with Rontis for the expansion of their cooperation, Nipro intends not only to strengthen its presence within the region of Latin America, but also to expand its scope within the regions of the Asia Pacific and Oceania.

**Nipro Corporation** was founded in 1954 and is headquartered in Osaka, Japan. Together with its subsidiaries, it engages in medical equipment, pharmaceuticals and glass businesses (which comprise the “trinity” business model for Nipro) in Japan, the United States of America, Europe and the rest of Asia.

**Rontis Corporation S.A.**, based in Zug, Switzerland, was established in 1986 and operates 3 manufacturing plants in Europe. It develops and manufactures interventional medical devices for coronary and peripheral minimally invasive procedures, including - among others - coronary drug eluting and bare metal stents, PTCA balloons & guidewires, peripheral stents and peripheral balloon dilatation catheters. Through the supply of the wide range product portfolio by Rontis, Nipro will further enhance the product line offered to the medical community, in addition to its existing IVR and coronary intervention devices and will now be in position to put more focus on the peripheral vascular treatment, in order to drive global growth for its entire vascular portfolio.

Nipro already develops, manufactures and markets interventional medical devices as a key strategic segment of its portfolio and, following the aforementioned agreement, it will proactively introduce and promote the related Rontis products in approximately 30 countries in Central & South America, Asia-Pacific & Oceania, in order to maximize the synergy effects.

By virtue of this extended exclusive distribution agreement, both Rontis and Nipro commit to continue contributing to society by serving additional healthcare needs of the market and assisting in improving patients' quality of life.

THE END

---

For further information, please contact Rontis' Corporate Communication Department at [media.relations@rontis.com](mailto:media.relations@rontis.com).

### **About Rontis Corporation**

Rontis is a privately-held specialty healthcare company, with its headquarters in Zug, Switzerland. It employs over 650 employees worldwide and is organized across 5 major divisions: Medical Devices, Pharmaceuticals, Infant Nutrition, Consumer Healthcare and Healthcare Services. It carries 30 years of experience within the wider Medical Device arena and the respective Division is active in R&D, manufacturing, marketing and international sales of its products & services. The Medical Devices Division is committed to the application of specialty minimally-invasive therapies for Interventional Cardiology & Radiology procedures by applying state-of-the-art methodologies in research & development and production.

For more information you can visit: [www.rontis.com](http://www.rontis.com)

### **About Nipro Corporation**

Nipro Corporation (8086: Tokyo) was founded in 1954 and is headquartered in Osaka, Japan. Together with its subsidiaries, it engages in medical equipment, pharmaceuticals, and glass businesses (which comprise the "trinity" business model for Nipro) in Japan, the United States, Europe and the rest of Asia.

In more detail, the company's Medical-Related Business segment offers injection and infusion products, artificial organ products, functional products, dialysis products, and diabetic products, as well as renal, intervention and anesthesiology, cardiopulmonary, and pharmaceutical kit products. Its Pharmaceutical-Related Business segment provides injectable drugs, including injection kits, etc.; oral drugs, such as orally-disintegrating tablets, etc.; generic anti-cancer drugs and biosimilars; and drugs for external use. The company's Glass-Related Business segment offers tube glass for pharmaceuticals, vials, and ampoules; and glass material products for thermos bottles and lighting. The consolidated sales of the last fiscal year for Nipro reached approximately the 2.3bn Euros.

For more information you can visit [www.nipro.com](http://www.nipro.com)